1. Introduction {#sec0001}
===============

Acute myeloid leukemia (AML) is a heterogeneous disease that is fatal in most patients. Without disease-directed therapy, essentially all patients will expire within weeks to months. Spontaneous remission (SR) of AML is a poorly understood and rare event, but it does occur, with multiple cases reported from the 1940's-present. SR is generally seen in the setting of acute infection, antibiotic use, or blood product transfusion, and an immune-mediated process has been postulated [@bib0001]. The time to relapse is generally short, with patients typically requiring standard treatment within a few months.

It is not clear if some SR cases, particularly the more durable ones, were actually a "leukemoid reaction", a non-malignant process characterized by an exaggerated immune response (usually to infection, e.g., *C. difficile colitis*) with marked leukocytosis and increased levels of pro-inflammatory cytokines and colony stimualitng factors (G-CSF/GM-CSF) \[[@bib0002],[@bib0003]\]. Classically, there is mature neutrophilia in the absence of blasts [@bib0004].

In this letter, we present a novel case of AML with NF1 mutation that achieved a durable SR in the setting of GI septicemia. We review the entire body of literature on SR-AML, and analyze the charactetisitcis of SR-AML patients, including those with both brief and prolonged SRs.

2. Case presentation {#sec0002}
====================

A 58-year-old Hispanic man with a history of ankylosing spondylitis previously treated with methotrexate and infliximab developed fever, abdominal pain, and hematochezia during a trip to Central America. On return to the United States, blood work revealed 6% circulating blasts, hemoglobin 12.3 g/dL, white blood count (WBC) 2.2 × 10^3^ cells/mm^3^, 7% neutrophils, 45% lymphocytes, 4% monocytes, 19% eosinophils, and 2% myelocytes. Platelets were 546 × 10^3^/mm^3^. Bone marrow biopsy demonstrated 40-50% blasts, left-shifted myelopoiesis, and trilineage dysplasia. No Auer rods were seen. The blasts were positive for CD34, CD117, MPO, CD13, and CD33. Cytogenetics were normal. Molecular testing (11-gene AML next generation sequencing \[NGS\] panel) was negative. His anemia worsened and he required blood transfusions. Intravenous antibiotics were started.

The patient was transferred to our hospital with ongoing bloody diarrhea and hypotension. Computed tomography (CT) imaging showed acute colitis. Upon arrival his WBC was 14 × 10^3^ cells/mm^3^ with neutrophilia and no circulating blasts, hemoglobin was 7.6 g/dL (transfusion dependent), and platelets were 1,006 × 10^3^/mm^3^. Repeat bone marrow examination showed 25% blasts with background dysplasia ([Fig. 1](#fig0001){ref-type="fig"}). AML induction was postponed as he was treated for GI septicemia.Fig. 1Bone marrow biopsy showing acute myeloid leukemia. The bone marrow aspirate smears show left shifted myelopoiesis with increased blasts (a). Blasts comprise 25% of bone marrow cellularity (b), with circulating blasts in peripheral blood (c) (a, 200X, b,c, 1000x; a-c, May-Grünwald Giemsa stain).Fig. 1

Over the next 2 weeks, the patient\'s symptoms resolved and his blood counts normalized. He underwent a third bone marrow biopsy \~4 weeks after the initial assessment ([Fig. 2](#fig0002){ref-type="fig"}), which demonstrated a cellular bone marrow (50-70%), increased megakaryocytes, and mild dyserythropoiesis. Blasts comprised 1% of total cells. The only abnormality was an NF1 mutation (c.4430+delT;splice-region) with variant allele frequency (VAF) 17% on an expanded NGS panel. Induction chemotherapy was deferred, and he was placed on observation.Fig. 2Bone marrow biopsy with no evidence of acute leukemia. The bone marrow core biopsy shows hypercellular bone marrow with increased megakaryocytes (a). The bone marrow aspirate smears show maturing hematopoiesis (b) with no increased blasts (c) (a, 200X, H&E stain; b,c, 1000x, May-Grünwald Giemsa stain)Fig. 2

Follow-up bone marrow biopsy 6 months after achieving SR demonstrated normocellular marrow (20-40%) with erythroid predominance and maturing trilineage hematopoiesis and no evidence of acute leukemia or myeloid neoplasm. NF1 gene reassessment could not be done due to insurance barriers. He remians in continuous SR for \>2 years at time of writing.

2.1. Analysis of reported cases {#sec0003}
-------------------------------

A PubMed search was performed using terms "acute leukemia", "remission", "regression", "spontaneous"; including only articles written in English. Infant and down syndrome cases were excluded. A total of 47 articles were examined, containing 55 cases of acute leukemia with SR. Among the 56 cases studied (including our patient), 33 patients were male (59%) and 23 were female (41%). The median age was 53.5 years. AML comprised 50 cases (89%), acute lymphocytic leukemia 4 cases (7%), and cutaneous myeloid sarcoma 2 cases (4%).

The mean time to relapse was 12.4 months. The median time to relapse was 5 months (range 2 weeks-NE). Sixteen of 56 patients had SR for \>12 months (not including 1 patient who received therapy after SR and remained in CR \>30 months). Of these 16 patients, 10 relapsed and 6 remained in CR at time of publication. For the 6 patients without relapse, follow-up was 14 months, 18 months, 24 months (our case), 29 months, 4 years, and 10 years. Of these 6 durable CRs, all had monocytic differentiation (M4/M5) except our case (5/6 cases). Five received antibiotics for acute infection (the one that did not received a GnRH agonist for misdiagnosed prostate cancer). Three additional patients had late relapse \>2 years after SR. Of note, there were patients in remission for \<1 year at date of last follow-up, and their long-term outcome is unknown.

When looking at all 56 cases, almost half were monocytic subtype by FAB (M4/M5). Cytogenetics were available for 42 cases: 15 patients (36%) had a normal karyotype (NK), 5 (12%) trisomy 8, 5 (12%) t(8;21), 4 (9%) 11q23/MLL re-arragenemnt, 2 inv(16), and 2 t(3;3)/EVI1 re-arragenemnt. Ten patients (24%) had other abnormalities. More recently, Grunwald et al., reported an AML patient with NPM1 mutation who had SR with loss of NPM1 mutation, but persistent background mutations such as TET2. His disease relapsed abruptly \~1 year later, with recurrence of NPM1 mutation [@bib0005].

Patients were reported to have an associated infection in 76% of cases and blood product transfusion in 45%. Less common associations were G-CSF, steroids, hydroxyurea, termination of pregnancy, GnRH, tumor lysis syndrome, discontinuation of lenalidomide, and Henoch-Schönlein purpura. 9% had no identifiable association. Among 42 cases with a presenting infection, 45% had pneumonia (n=19) and 16% bacteremia (n=7). Other sources included upper respiratory, urinary, GI tract, skin, disseminated tuberculosis, and liver abscess.

3. Discussion {#sec0004}
=============

Our patient had histologic diagnosis of AML with \>20% myeloblasts on two subsequent marrow examinations. After treatment of concurrent GI sepsis, he entered SR and has been in continuous CR for 24 months. On review of SR in the literature, it is clear the vast majority of patients relapse, with most relapses occurring early (\<1 year). Patients were typically younger, de novo, and monocytic. Interestingly, most had a cytogenetic abnormality (e.g. +8, core-binding factor (CBF) fusion, and MLL- and EVI1-rearragements; 36% had NK). Most patients with SR have an associated factor such as infection, but the causality has been opaque.

Of the 16 known patients with durable SR for \>12 months, 6 (40%) have not relapsed. Of these 6, 5 had monocytic subtype and 5 had a concomitant infection at diagnosis. Three had a NK and 2 MLL-AF9 fusion (1 did not have cytogenetics available). This raises the question: are durable SRs attributable to: (1) driver-mutated AML undergoing SR via unknown mechanism (e.g. the MLL-rearranged cases), or (2) exaggerated, blastic "leukemoid reaction" in the setting of CH. Microbial products, such as endotoxin and nucleic acids, are potent stimuli for CSF production [@bib0006], and pharmacologic CSF exposure can induce a blastic marrow response [@bib0007].

Our patient presented with GI sepsis and hemorrhagic colitis, a known cause of leukemoid response [@bib0008]. Interestingly, he did not present with leukocytosis, the *sine-qua-non* of leukemoid reaction, but rather with leukopenia, although he did have a left-shift and marked thrombocytosis. Our patient\'s self-resolving blast increase and dysplastic features, normal cytogenetics, and long duration of SR, support that he may have had an atypical marrow stress response in the setting of isolated *NF1* mutation.

The *NF1* gene is a tumor suppressor and negative regulator of RAS. The canonical hereditary mutation is associated with neurofibromatosis Type 1, where the risk of myeloid leukemias is 200 -- 500 times higher than the general population \[[@bib0009],[@bib0010]\]. Somatic *NF1* mutations are found in \~5-7% of de novo AML, and are associated with poor prognosis [@bib0011], [@bib0012], [@bib0013], [@bib0014]. Reports of high VAF and presence of the mutation in hematopoietic stem cells (HSCs) suggests that *NF1* may act as a driver or founder mutation in some AML patients and it is not a common CH gene \[[@bib0011],[@bib0012],[@bib0015]\]. *NF1* mutations occur throughout the gene and consist primarily of truncating frameshift mutations but also missense, nonsense, and indels with a recent hotspot mutation characterized in 27% of AML NF1 mutants at Threonine 676, which leads to nonsense-mediated mRNA decay [@bib0012]. The *NF1* mutation in our patient at c.4430+delT targets Arginine 1477 with a deletion causing frame-shift in a splice region, which would be expected to cause premature termination and truncated protein sequence lacking the c-terminal nuclear localization signal. Missense and splice mutations at R1477 in *NF1* have been previously identified in 7 patients with solid tumors and are predicted to be pathogenic (COSMIC); however, this is the first time it has been reported in AML.

We report a novel NF1 mutation in AML and one of the first cases of AML-SR with NGS data available. Whether our patient had self-limited blast proliferation/self-renewal in the setting of CH, or de novo AML with true SR, it is important to consider both possibilities when triaging leukemic patients presenting with intercurrent infection and reactive blood counts/unexplained count recovery. In the \>50 cases we analyzed, while most SRs occured in the setting of severe physiologic stress, over half also had a recurrent cytogenetic abnormality (including 11 patients with AML-defining gene fusion), implicating an autologous mechanism than can induce remission in frank AML, although this is rarely durable, [Table 1](#tbl0001){ref-type="table"}.Table 1Summary of our case and all cases reported in the literatureTable 1Year/ First authorAge/GenderFAB SubtypeCytogenetics/MutationsAssociated factors or characteristicDuration of remission1. 1949 -- Birge33 FAML-M5bNot disclosedEclampsia, termination of pregnancy22 months2. 1979 -- Lanchant67 FAML-M1Not disclosedPneumonia17 months3. 1982 -- Ruutu -- 3534 MAML-M5bNormalFever2 months4. 1985 -- Ifrah56 MAML-M150 XXY, +4, +8, +14, +t(21q,22q), -21, -22Disseminated tuberculosis, blood transfusion, leukocyte transfusion34 months5. 1986 -- Jehn34 MAML-M4Partial del(16)Pneumonia, ear infection, blood transfusion5 months6. 1988 -- Kizaki53 FAML -- hypoplasticNormalFever, antibiotic use5 months7. 1989 - Antunez de Mayolo28 FAML-M3Aneuploidy (with extra chromosome in group C)Fever, antibiotic treatment, blood transfusion3 months8. 1990 -- Spadea69 MAML-M5aNot disclosedNone3 months9. 1991 -- Narayanan64 MAML-M446XY, del(5)(q13;q31)Blood transfusion, *S. aureus* bacteremia8 months10. 1993 -- Jimenez72 FAML-M03n hyperploidPneumonia, *S. epidermidis* bacteremia, blood transfusion, remote history of CHT for AML (ineffective)5 months11. 1993 -- Kang19 MAML-M3Not disclosedPurulent cellulitis7months12. 1993 -- Kang19 FAML-M3Not disclosedTuberculosis pneumonia14 months13. 1994 -- Paul74 FAML-M5Two clones: {1}46XX, t(9;11)(p22;q23)\
{2}52XX, +3, +8, +8, +14, +19, +t(9;11) (p22;q23)None7 months14. 1994 -- Musto49 FAML-M5aNot disclosedConcomitant Henoch-Schönlein syndrome.6 months15. 1994 -- Delmer48 MAML-M245 × 0, t(8;21)Gram-negative and *Candida albicans* sepsis, blood transfusion36 months16. 1994 -- Delmer41 FAML-M5NormalProlonged fever of unknown origin, blood transfusion14 months17. 1994 -- Delmer54 MAML-M2NormalGram-negative sepsis, blood transfusion3 months18. 1996 -- Mitterbauer64 MAML-M5bNot disclosedSepsis, *E. faecium* bacteremia, hydroxyurea, blood transfusion\> 14 months19. 1996 -- Mitterbauer83 MAML-M2t(8;21)(q22;q22) AML1/ETO, del(7)(q22)Pneumonia, G-CSF, blood transfusion1 month20. 1997 -- Takahashi64 MUnclearNot disclosedPneumonia, G-CSF4 months21. 1997 -- Takahashi54 MUnclear47 XX, +8Pneumonia, G-CSF3 months22. 1997 -- Takahashi70 MUnclearNot disclosedG-CSF, blood transfusion17 months23. 2000 -- Takezako79 FALL-TNot disclosedPneumonia, antibiotic use1 year24. 2000 -- Martelli26 FAML-M4E46 XX, inv(16)(p13q22), CBFB/MYH11 +Interstitial pneumonia, antibiotics, hydroxyurea, blood transfusion1 month (patient received CHT and relapsed 25 months later)25. 2001 -- Tzankov60 FAML -- M1NormalAcute tonsillitis, pneumonia, G-CSF, blood transfusion,10 months26. 2001 -- Shimohakamada71 FAML-M245 × 0, -1, +4(q31), t(8;21)(q22;q22), AML1/MTG8Pneumonia, blood transfusion, high-dose methylprednisolone4 months then lost follow-up27. 2004 -- Mayald31 MAML-M5aNormalFever, group B streptococci bacteremia, antibiotic treatment2 months28. 2004 -- Müller61 MAML-M5aT(9;11)(q22;q23); MLL/AF9 fusion.Fever, antibiotic treatment\> 29 months29. 2004 -- Fozza72 MAML-M048 XY, del(6)(p22-pter), +13, +14Pneumonia, sputum positive for coagulase-negative *S. aureus* and *Candida spp.* Blood transfusion, steroids5 months30. 2006 -- Tsavaris64 MAML-M4NormalGnRH agonist therapy\> 4 years31. 2006 -- Al-Tawfiq47 MAML-M5bNormalPerforated bowel, *Clostridium septicum* bacteremia4 months32. 2007 -- Trof29 MAML-M245 × 0, t(8;21)Infection, antibiotic use, blood transfusion3 months33. 2007 -- Trof28 MAML-M5bNormalBeta-hemolytic Streptococci bacteremia, blood transfusionsReceived consolidation CHT after SR. Relapse 4 weeks after SCT.34. 2007 -- Daccache83 FAML-M5b47 XX, trisomy 8Antibiotics for possible UTI; blood transfusion2 weeks35. 2007 -- Hudecek35 FAML-M148 XX, del(3)(q21), +6, t(11;15)(q23;q15), +21. 11q23/MLL abnormalityBlood transfusion, prophylactic antibiotics\> 8 months36. 2008 -- Yoruk4 FT-ALLNot disclosedFever, possible pneumonia versus upper respiratory infection4 weeks37. 2008 -- Jain66 FAML-M4Trisomy 8*Candida* pneumonia29 months38. 2008 -- Jain72 FAML-M5bNot availableNone5 months39. 2008 -- Jain46 MAML-M5bNot availableLiver abscess2 months40. 2009 -- Chen14 MALL-BNormalPneumonia, tumor lysis syndrome, MRSA, *S. viridans* and coagulase-negative *Staphylococcus* in pleural fluid14 days41. 2009 -- Marisavljevic63 MAML-M246XY, del(6)(q21)Blood transfusion6 months42. 2010 -- Teng75 MAML-M2Trisomy 8Blood transfusion, pneumonia21 weeks43. 2012 -- Xie42 MAML-M5aNormalPneumonia, G-CSFBlastic plasmacytoid dendritic cell neoplasm 40 months after initial diagnosis44. 2012 -- Müller-Schmah61 FAML-M5at(9;11), MLL-AF9Fever, *S. aureus* bacteremia, antibiotics administration\> 10 years45. 2013 -- Zeng34 FCutaneous myeloid sarcoma46 XX, normalBlood transfusion, fever1 month46. 2013 -- Zeng31 MAML-M246 XY, t(8;21)(q22;q22), del(9)(q22,q34)Pulmonary infection by *Serratia marcescens*2 months47. 2014 -- Adam35 MAML-M4Not disclosedBlood transfusion, possible infection6 weeks48. 2014 -- Kazmierczak77 MAML-M448 XY, +13, +21Blood transfusion, low dose steroids7 months49. 2014 -- Purhoit46 MALL-BNormalAcinetobacter spp. bacteremia, infective endocarditis, possible fungal pneumonia9 weeks50. 2015 -- Takahashi79 FAleukemic cutaneous myeloid sarcomaTrisomy 8No associated factor2 months51. 2017 -- Hoshino49 FAML-M5a46,XX,t(8;16)(p11;p13), *MOZ-CBP* fusionNone. Received BMT 4 months after SR.4 months, at least.52. 2017 -- Kremer51 MAML-M445 XY, t(3;3)(q21;q26), der(17)t(17;21)(p11.2;q11;2)Previous lymphoma / discontinuation of lenalidomide5 months53. 2017 -- Mozafari53 MAML-M4NormalPulmonary infection\> 18 months54. 2018 -- Höres31 FALL46XX, del(5)(q13;q22); ACSL6 deletion.Pregnancy, blood transfusion, GI infection\> 30 months (had SR but also received therapy)55. 2019 -- Grunwald72 MAML- M2Normal, Mutated NPM1, RUNX1, NRAS, TET2, U2AF1, PRPF8Blood transfusion, leukemia cutis\~12 months (relapsed)56. 2019 -- Bradley58 MUnclear (had MDS changes)Normal; Deletion of NF1 geneGI septicemia\> 24 months (f/u ongoing)
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